Health Catalyst (NASDAQ:HCAT) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of Health Catalyst (NASDAQ:HCAT) from a hold rating to a buy rating in a research note released on Monday, Zacks.com reports. The brokerage currently has $46.00 price objective on the stock.

According to Zacks, “Health Catalyst Inc. is a provider of data and analytics technology and services to healthcare organizations. Health Catalyst Inc. is based in Salt Lake City, Utah. “

Several other research firms have also weighed in on HCAT. Cantor Fitzgerald assumed coverage on Health Catalyst in a report on Tuesday, October 29th. They set an overweight rating and a $47.00 target price on the stock. JPMorgan Chase & Co. began coverage on Health Catalyst in a research report on Monday, August 19th. They issued an overweight rating and a $50.00 price target for the company. Svb Leerink started coverage on Health Catalyst in a report on Monday, August 19th. They issued an outperform rating and a $55.00 target price on the stock. SunTrust Banks began coverage on Health Catalyst in a research report on Monday, August 19th. They issued a buy rating and a $53.00 price objective for the company. Finally, Evercore ISI started coverage on shares of Health Catalyst in a research report on Monday, August 19th. They set an outperform rating and a $50.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $50.22.

HCAT opened at $40.50 on Monday. Health Catalyst has a 1 year low of $26.00 and a 1 year high of $49.85. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.24. The company’s fifty day moving average price is $34.95.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.10. The firm had revenue of $39.40 million during the quarter, compared to analysts’ expectations of $37.77 million. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, analysts predict that Health Catalyst will post -1.13 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of HCAT. Emerald Advisers LLC bought a new stake in shares of Health Catalyst in the 3rd quarter worth approximately $631,000. Orbimed Advisors LLC bought a new stake in shares of Health Catalyst during the third quarter valued at approximately $5,682,000. Nepsis Inc. acquired a new position in shares of Health Catalyst in the third quarter valued at $3,101,000. Conestoga Capital Advisors LLC acquired a new position in shares of Health Catalyst in the third quarter valued at $3,249,000. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Health Catalyst in the third quarter valued at $485,000. Hedge funds and other institutional investors own 45.63% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.

See Also: What is systematic risk?

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.